captivate: ibrutinib and venetoclax in cll
Published 2 years ago • 347 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
5:54
updates from captivate: ibrutinib and venetoclax for cll
-
1:34
captivate study: outcomes in patients with umrd following cessation of ibrutinib plus venetoclax
-
1:23
captivate: fixed-duration ibrutinib plus venetoclax in patients with cll/sll
-
2:04
captivate: ibrutinib/venetoclax delivers high rates of umrd in cll
-
2:14
positive results for captivate: ibrutinib and venetoclax for cll
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
7:29
venetoclax obinutuzumab: impact on cll management
-
4:52
apoptosis and venetoclax
-
1:28
ibrutinib and venetoclax: a powerful combination in frontline and relapsed cll
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
1:02
combination therapies in cll: ibrutinib and venetoclax
-
2:18
first-line ibrutinib and venetoclax in cll
-
1:17
exploratory analysis of the clarity study: ibrutinib plus venetoclax in patients with r/r cll
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:56
emerging ibrutinib-based combinations in cll
-
2:50
venetoclax and ibrutinib based approaches in cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:39
retreatment with a btki plus venetoclax after relapse is effective in cll: insights from captivate
-
3:22
combining venetoclax and obinutuzumab in the treatment of cll
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll